FCBCure wraps transformation with two new leadership hires

Joe Soto and Steven Hebert will act as co-managing directors for FCB Health's New Jersey office, FCBCure.

After 18 months of consolidation and change, FCB Health has appointed Joe Soto and Steven Hebert as the new co-managing directors for its New Jersey office, FCBCure.

The experienced pair joins from Saatchi & Saatchi Wellness, where Soto was the head of the account team and Hebert was in charge of the creative team for the past four years. Soto and Hebert will replace co-managing directors Christine Finamore and Tom Millar. Finamore is pursuing new opportunities, while Millar will rejoin FCB Health in Manhattan in a creative leadership role, Dana Maiman, CEO of FCB Health, told FiercePharma. For Soto, the move is a return “home,” as he worked as a senior account executive for FCB Healthcare in San Francisco from 2001 to 2004.

FCBCure was formerly a group of ICC Lowe health agency brands, which was consolidated into the larger FCB Health company by parent Interpublic Group in March 2015. The name was changed to FCBCure later that year, and the offices in Parsippany, NJ, were renovated for the newly combined 130-plus member staff. Clients include Allergan, Bayer, DSI, Heron, J&J Vision Care, Ophthotech and Vertex.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Maiman said she believes Soto and Hebert will continue to push forward the positive momentum FCB Cure is riding and are the right management team to take the agency to the next level.

“They bring such tremendous energy that is often found more in the agencies in New York (City). But we know there are so many incredibly talented folks in New Jersey, and I think they’ll be a great magnet for those people,” she said.

“FCBCure is more than just a name. It is an aspiration, a promise we make to our clients and ourselves," Hebert said in a statement. "It says that we won’t stop, we won’t relent, we won’t back down until we have solved a problem completely.”

Suggested Articles

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.